A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours

M Rasschaert, D Schrijvers, J Van den Brande, J Dyck, J Bosmans, K Merkle, J B Vermorken, M Rasschaert, D Schrijvers, J Van den Brande, J Dyck, J Bosmans, K Merkle, J B Vermorken

Abstract

The aim of the study was to determine the maximum tolerated dose (MTD), the dose limiting toxicity (DLT), and the pharmacokinetic profile (Pk) of bendamustine (BM) on a day 1 and 2 every 3 weeks schedule and to recommend a safe phase II dose for further testing. Patients with solid tumours beyond standard therapy were eligible. A 30-min intravenous infusion of BM was administered d1+d2 q 3 weeks. The starting dose was 120 mg m(-2) per day and dose increments of 20 mg m(-2) were used. Plasma and urine samples were analysed using validated high-performance liquid chromatography/fluorescence assays. Fifteen patients were enrolled. They received a median of two cycles (range 1-8). The MTD was reached at the fourth dose level. Thrombocytopaenia (grade 4) was dose limiting in two of three patients at 180 mg m(-2). One patient also experienced febrile neutropaenia. Lymphocytopaenia (grade 4) was present in every patient. Nonhaematologic toxicity including cardiac toxicity was not dose limiting with this schedule. Mean plasma Pk values of BM were tmax 35 min, t(1/2) 49.1 min, Vd 18.3 l m(-2), and clearance 265 ml min(-1) m(-2). The mean total amount of BM and its metabolites recovered in the first micturition was 8.3% (range 2.7-26%). The MTD of BM in the present dose schedule was 180 mg m(-2) on day 1+2. Thrombocytopaenia was dose limiting. The recommended dose for future phase II trials with this schedule is 160 mg m(-2) per day.

References

    1. Barmam Balfour JA, Goa KL (2001) Bendamustine. Drugs 61: 631–640
    1. Bergmann M, Goebeler M, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, Hallek M (2005) Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 90: 1357–1364
    1. Bezek S, Kukan M, Scasnár V, Lukásková M, Trnovec T (1996) Selective uptake of the anticancer drug bendamustine by liver and kidney tissues following its intravenous administration to mice. Methods Find Exp Clin Pharmacol 18: 117–122
    1. Bezek S, Scasnár V, Trnovec T, Grupe R (1991) Hepatobiliary elimination of bendamustin (Cytosan®) in rats. Pharmazie 46: 810–811
    1. Bremer K (2002) High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 128: 603–609
    1. Chow KU, Boehrer S, Geduldig K, Krapohl a, Hoelzer D, Mitrou P, Weidmann E (2001) In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 86: 485–493
    1. Chow KU, Nowak D, Boerher S, Ruthardt M, Knau A, Hoelzer D, Mitrou P, Weidmann E (2003) Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol 66: 711–724
    1. Friedberg J, Cohen P, Kerr R, Robinson KS, Forero-Torres A, van der Jagt R, Camacho E, Hainsworth J, Roeck B, Multani P (2004) SDX-105 demonstrates a high response as a single-agent with acceptable safety in rituximab-refractory, relapsed indolent or transformed non-Hodgkin's lymphoma (NHL). ASH Annual meeting abstracts 2004. Blood 104(11): [abstract 2480]
    1. Gandhi V (2002) Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Sem Oncol 29(4 Suppl 13): 4–11
    1. Heider A, Niederle N (2001) Efficacy and toxicity of bendamustine in patients with relapsed low-grade non Hodgkin's lymphomas. Anti-Cancer Drugs 12: 725–729
    1. Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann C, Klinkenstein C, Schulze M, Arzberger H, Bremer K, Hahnfeld S, Schwarzer A, Müller C, Müller Chr (2006) Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 132: 105–112
    1. Höffken K, Merkle Kh, Schönfelder M, Anger G, Brandtner M, Ridwelski K, Seeber S (1998) Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 124: 627–632
    1. Horn U, Härtl A, Güttner J, Hoffmann H (1985) Toxicity of the alkylating agent Bendamustin. Arch Toxicol 8(Suppl): 504–506
    1. Kanekal S, Crain B, Elliot G (2004) SDX-105 (Treanda™) enhances the tumor growth inhibitory effect of rituximab in daudi lymphoma xenografts, ASH annual meeting abstract 2004. Blood 104(11): [abstract 4580]
    1. Konstantinov SM, Kostovski A, Topashka-Ancheva M, Genova M, Berger MR (2002) Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol 128: 271–278
    1. Leoni LM, Bailey B, Reifert J, Niemeyer C, Bendall H, Dauffenbach L, Kerfoot C (2004) In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. Proc Am Assoc Cancer Res 45, [abstract 1215]. (As indicated on the website of the AACR)
    1. Lissitchkov T, Arnaudov G, Peytchev D, Merkle K (2006) Phase I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 132: 99–104
    1. Matthias M, Preiss R, Sohr R, Possinger K (1995) Pharmacokinetics of bendamustin in patients with malignant tumors. Proc Am Soc Clin Oncol 14: 458 (abstract 1476)
    1. Niemeyer C, Bailey B, Reifert J, Bendall H, Corbeil J, Leoni LM (2004) SDX-105 (Bendamustine) is a clinically active chemotherapeutic agent with a distinct mechanism of action. Proc Am Assoc Cancer Res 45, [abstract 1129]. (as indicated on the website of the AACR)
    1. Ozegowski W, Krebs D (1963) w-[bid-(β-chloroethyl)-amino-benzimazolyl-(2)]-propionic or butyric acids as potential cytotoxic agents. J Pract Chem 20: 178–186
    1. Pönisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, ubert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D (2006) Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 132(4): 205–212
    1. Preiss R, Matthias M, Merkle KH (1998) Pharmacological and clinical data of bendamustine. Proceedings of the 17th International Cancer Congress Rio de Janeiro, 24–28 August 1998, Monduzzi Editore S.p.A. Bologna: pp. 1637–1640
    1. Pyke K, Tschakovsky M (2005) The relationship between shear sterss and flow-mediated dilation: implications for the assessment of endothelial function. J Physiol 568: 357–369
    1. Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle KH, Vermorken JB (2007) A phase I study of bendamustine hydrochloride administered once every three weeks in patients with solid tumors. Anti Cancer Drugs 18: 587–595
    1. Reck M, Haering B, Koschel G, Kaukel E, von Pawel J, Gatzemeier U (1998) Chemotherapie des fortgeschrittenen nicht-kleinzelligen und kleinzelligen bronchialkarzinoms mit bendamustin – Eine phase II Studie. Pneumologie 52: 570–573
    1. Rummel M, Al-Batran S, Kim S, Welslau M, Hecker R, Kofahl-Krause D, Josten K, Dürk H, Rost A, Neise M, von Grünhagen U, Chow K, Hansmann M, Hoelzer D, Mitrou P (2005a) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23: 3383–3389
    1. Rummel M, Al-Batran S, Welslau M, Kofahl-Krause D, Duerk H, Hoelzer D, Mitrou P (2005b) Bendamustine and rituximab act synergistically in vitro and are effective in the treatment of relapsed or refractory indolent and mantle cell lymphomas. Proc Am Soc Clin Oncol 24: 576s (abstract 6565).
    1. Schmittel A, Knodler M, Hortig P, Schulze K, Thiel E, Keilholz U (2007) Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 55(1): 109–113
    1. Schöffski P, Hagedorn T, Grünwald V, Paul H, Merkle K, Kowalski R, Ganser A (2000a) Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours. J Cancer Res Clin Oncol 126: 41–47
    1. Schöffski P, Seeland G, Engel H, Grünwald V, Paul H, Merkle K (2000b) Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. Ann Oncol 11: 729–734
    1. Schrijvers D, Vermorken JB (2002) Phase I studies with bendamustine: an update. Semin Oncol 29(4 Suppl 13): 15–18
    1. Schwänen C, Hecker T, Hübinger G, Wölfe M, Rittgen W, Bergmann L, Karakas T (2002) In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 16: 2096–2105
    1. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7: 415–421
    1. Teichert J, Baumann F, Chao Q, Franklin C, Bailey B, Hennig L, Caca K, Schoppmeyer K, Patzak U, Preiss R (2006) Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamusitne hydrochloride. Cancer Chemother Pharmacol September 7 [E-pub ahead of print].
    1. Teichert J, Mockel J, Pönisch W, Seidel A, Lotfi M, Matthias M (2003) Influence of hepatic and renal function on the pharmacokinetics of bendamustine. Int J Clin Pharmacol Ther 41: 564
    1. Teichert J, Sohr R, Baumann F, Hennig L, Merkle K, caca K, Preiss R (2005) Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine and plasma from patients with cholangiocarcinoma. Drug Metab Dispos 33: 984–992
    1. Von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R, Marschner N, Kleeberg U, Tsekov C, Fritze D, Thomssen C, Stuart N, Vermorken JB, Loibl S, Merkle Kh, Kaufmann M (2005) Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 16(8): 871–878
    1. Weber H, Amlacher R, Preiss R, Hoffmann H (1991) Pharmakokinetik von bendamustin (Cytostasan®) in B6D2F1-Mäusen. Pharmazie 46: 589–591
    1. Weidmann E, Kim S, Rost A, Schuppert H, Seipelt G, Hoelzer D, Mitrou P (2002) Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 13: 1285–1289
    1. Zulkowski K, Kath R, Semrau R, Merkle Kh, Höffken K (2002) Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J Cancer Res Clin Oncol 128: 111–113

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe